Navigation Links
Forte Research Systems Unveils the Allegro™ Research on Demand Cloud-Based Product Line
Date:11/18/2010

MADISON, Wis., Nov. 18, 2010 /PRNewswire/ -- Forte Research Systems, makers of OnCore® , the most widely adopted clinical research platform among academic research organizations and cancer centers in the United States, unveiled a new product line today, the Allegro™ Research on Demand, cloud-based clinical research management solution. The first product in the new line is Allegro CTMS@Site™, the clinical trials management system built exclusively for investigational sites.

(Photo: http://photos.prnewswire.com/prnh/20101118/CG04162)

(Photo: http://www.newscom.com/cgi-bin/prnh/20101118/CG04162)

(Logo: http://photos.prnewswire.com/prnh/20101115/CG02078LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101115/CG02078LOGO)

Research coming out of Tufts Center for the Study Drug Development shows that over half of the clinical research being conducted worldwide is taking place in physician practices, community hospitals, and dedicated research sites. These relatively small sites are experiencing trends in the industry in ways that are distinct from large research organizations.

"Trends in the industry are creating a significant increase in administrative overhead and regulatory exposure for the sites," said Srini Kalluri, founder, president & CEO of Forte Research Systems. "We built Allegro CTMS@Site to address these specific challenges from the sites' perspective."

Pharmaceutical companies conducting clinical trials on new drugs are spreading the work among more sites as a way to increase the probability of success and to reach more potential patient participants. In turn, this trend has led individual sites to take on more trials. At the same time, while sites are grappling with more trials, the trials are becoming much more complex with a proliferation of procedures and subject eligibility criteria.

In an attempt to be more competitive and efficient in this environment, today's sites are implementing tighter financial management, overseeing regulatory compliance more intensively, striving to achieve status as a preferred partner, and adopting clinical trials management systems (CTMS) to streamline operations and replace paper-based processes.

"When it comes to CTMS, current solutions in the marketplace leave a lot to be desired," said Kalluri.

With what is currently available, sites have to choose between products with bloated functionality and complex interfaces that require up-front investments in infrastructure, have ongoing maintenance and administrative overhead, and have long training cycles with slow user adoption rates.

By contrast, the Allegro product line is built for clinical research operations excellence with no software to install and no systems administration required, real-time visibility into the entire clinical research portfolio, and a user-centric, intuitive interface that is easy to use, virtually eliminating the need for training. With Allegro CTMS@Site, sites can get up and running in a single day.

Founded in 2000 and headquartered in Madison, Wisconsin, Forte Research Systems, Inc. develops clinical and translational research management software. The company's flagship product, the OnCore® system, is the nation's most widely adopted clinical research platform among academic research organizations and cancer centers.

PercipEnz Technologies is now Forte Research Systems. Same company, new name.


'/>"/>
SOURCE Forte Research Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
2. ForteBio Announces Launch of Protein G Biosensor for Use on Companys Octet® Instruments
3. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
4. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
5. FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
6. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
7. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
8. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
9. CVS Caremark Research Finds Correlation Between Amount of Patient Co-pay and Prescription Abandonment
10. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
11. New Peripheral Vascular Device Market Research Data Covering Multiple Geographies Released by Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition ... muscular dystrophy, and funding for Duchenne research, participated in the April 25 U.S. ... Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in ...
(Date:4/29/2016)... ... 29, 2016 , ... The Society for Assisted Reproductive Technology ... required to report in vitro fertilization (IVF) delivery rates to both ... of assisted reproductive technologies in the United States. , This year, SART’s ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... The ... the workforce is aging – meaning that there is an urgent need for highly ... and interactive training solution, delivering a multi-pronged approach to train and retain care managers, ...
Breaking Medicine News(10 mins):